Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003

NCT02348008 is registered in ClinicalTrials.gov with Arkadiusz Z. Dudek, MD as lead sponsor.

NCT NCT02348008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02348008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003
Lead sponsor
Arkadiusz Z. Dudek, MD
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2015
Completion date
December 5, 2019
Enrollment
61 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal carcinoma